Fact CheckerSign in

NCT06661616Completed

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by Electroconvulsive Therapy in the Treatment of Depression

Source: ClinicalTrials.gov · Last updated 28 Oct 2024

Brief summary (registry, in English)

Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.

Status (registry)
Completed
Study type
Observational
Enrollment
87 (actual)
First submitted
24 Oct 2024
Start date
6 Jun 2018
Primary completion date
14 May 2024
Lead sponsor
Centre Hospitalier St Anne
NCT number
NCT06661616

What you commit to

  • Study type: Observational
  • Participants enrolled: 87
  • From 6 Jun 2018 to the primary completion date, 14 May 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Study population: depressed subjects with ECT
    • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco
    • Neurological comorbidity: Parkinson's disease, dementia
    • ECT treatment in the 6 months prior to inclusion
    • Compulsory care
    • Protected adults, persons under court protection measures
    • Persons deprived of liberty by judicial or administrative decision;
    • Refusal of consent to ECT treatment
    • Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia)
    • Contraindications to MRI (patients with metal prostheses, claustrophobia)
    • Pregnant or breast-feeding women
  • Control population: depressed subjects without ECT
    • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on any substance other than tobacco
    • Neurological comorbidity: Parkinson's disease, dementia
    • ECT treatment in the 6 months prior to inclusion
    • Compulsory care
    • Protected adults, persons under court protection measures
    • Persons deprived of liberty by judicial or administrative decision;
    • Pregnant or breast-feeding women

Other illness

  • Control population: healthyvolunteers
    • Protected adults, persons under legal protection,
    • Persons deprived of their liberty by judicial or administrative decision ;
    • persons hospitalised for purposes other than research
    • Clear psychiatric history
    • Dependence on any substance other than tobacco
    • Neurological history: Parkinson's disease, dementia
    • Pregnant or breast-feeding women

Who the study is looking for

  • Study population: depressed subjects treated with ECT
    • Male or female over 18 years of age
    • Hospitalised at the Centre Hospitalier Sainte-Anne
    • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
    • Indication for ECT treatment
    • Patient has given informed written consent
    • Beneficiary of a social security scheme
  • Control population: depressed subjects treated without ECT
    • Male or female over 18 years of age
    • Hospitalised at the Centre Hospitalier Sainte-Anne
    • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
    • Patient who has given informed written consent
    • Beneficiary of a social security scheme
  • Control population: healthy volunteers
    • Male or female over 18 years of age
    • Patient with written informed consent
    • Beneficiary of a social security scheme

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sainte-Anne Hospital (GHU Paris Psychiatrie et Neurosciences)
Coordinator of this site? Confirm its status
ParisFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression (NCT06661616) – Frontlight Research